阿库斯生物科学
RCUS
22.12
-0.70
-3.07%
阿库斯生物科学
US · RCUS
#2467 按市值排名
上市于 2018
22.12
-0.70
-3.07%
实时 - 追踪5344个代码 - 心跳于501秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 98.36% +0.06pp
- 机构数量
- 289 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund49.24%
Public Company26.87%
Hedge Fund17.62%
Individual/Insider3.61%
VC/PE Fund2.76%
Private Company0.87%
Government Pension Fund0.77%
Insurance Company0.21%
主要股东 截至 2026-08-05
Gilead Sciences, Inc.
24.68% · 31.42M 股
BlackRock
12.89% · 16.42M 股
State Street Global Advisors
4.74% · 6.03M 股
Wellington Management Group
4.63% · 5.90M 股
Montanova Capital, LLC
3.75% · 4.78M 股
Vanguard Capital Management, LLC
3.54% · 4.50M 股
Vanguard Portfolio Management, LLC
3.51% · 4.48M 股
FMR
3.18% · 4.05M 股
Citadel Advisors LLC
2.46% · 3.14M 股
Woodline Partners LP
2.36% · 3.01M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 22次买入 · 28次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Gilead Sciences, Inc. | -- | 24.68% |
| Terry Rosen | Chairperson & CEO | 2.04% |
| Juan Jaen | Co-Founder & President | 0.86% |
| Yasunori Kaneko | Lead Independent Director | 0.15% |
| Kathryn Falberg | Independent Director | 0.13% |
| Jennifer Jarrett | Chief Operating Officer | 0.10% |
| Carolyn Tang | General Counsel | 0.09% |
| David Lacey | Independent Director & Member of Scientific Advisory Board | 0.06% |
| Antoni Ribas | Independent Director & Member of Scientific Advisory Board | 0.04% |
| Andrew Perlman | Independent Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-20 | Alexander Azoy | VP of Finance & Principal Accounting Officer | Derivative Exercise and Sale | -2,827 | $15.44–30.00 |
| 2026-07-09 | Juan Jaen | Co-Founder & President | Open Market Disposition | -68,569 | $28.61–30.05 |
| 2026-06-23 | Juan Jaen | Co-Founder & President | Automatic Disposition | -31,431 | $27.03–29.66 |
| 2026-06-10 | Yasunori Kaneko | Lead Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Kathryn Falberg | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Andrew Perlman | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | C. Machado | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | David Lacey | Independent Director & Member of Scientific Advisory Board | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Antoni Ribas | Independent Director & Member of Scientific Advisory Board | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Carolyn Tang | General Counsel | Derivative Exercise and Retained | +34,090 | $2.57 |
| 2026-06-10 | Nicole Lambert | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-05-31 | Alexander Azoy | VP of Finance & Principal Accounting Officer | Automatic Disposition | -2,562 | $25.77 |
| 2026-05-10 | Robert Goeltz | Principal Financial Officer & CFO | Open Market Disposition | -7,763 | $25.63 |
| 2026-05-05 | Jennifer Jarrett | Chief Operating Officer | Intent to Sell (Form 144) | -77,793 | $24.60 |
| 2026-04-22 | Jennifer Jarrett | Chief Operating Officer | Intent to Sell (Form 144) | -53,826 | $25.20 |
| 2026-04-07 | Jennifer Jarrett | Chief Operating Officer | Intent to Sell (Form 144) | -70,000 | $22.57 |
| 2026-01-22 | Juan Jaen | Co-Founder & President | Other Acquisition | +31,000 | -- |
| 2026-01-22 | Juan Jaen | Co-Founder & President | Other Derivative Acquisition | +126,000 | $22.13 |
| 2026-01-22 | Robert Goeltz | Principal Financial Officer & CFO | Other Acquisition | +24,000 | -- |
| 2026-01-22 | Robert Goeltz | Principal Financial Officer & CFO | Other Derivative Acquisition | +96,000 | $22.13 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:18 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿库斯生物科学 讨论区 0 条评论